
|Videos|April 23, 2022
Study: Effects of two dosing regimens of Netarsudil in patients with Fuchs corneal dystrophy
Author(s)Sheryl Stevenson
Richard L. Lindstrom, MD, of Minnesota Eye Consultants, discusses his ASCRS presentation, "Randomized, Open-Label, Parallel-Group Study of Two Dosing Regimens of Netarsudil in Patients with Fuchs Corneal Dystrophy," with Ophthalmology Times' Sheryl Stevenson.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
First patient treated in ViaLase’s IDE trial
2
Iolyx Therapeutics and Laboratoires Théa enter into agreement over ILYX-002 for the treatment of OSD
3
Formosa Pharmaceuticals and Rxilient sign licensing and commercialization agreement for APP13007
4
PainReform launches development plan for OcuRing-K, readies phase 2 trial
5















































.png)


